Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
Caputo A, Racine A, Paule I, Tariot PN, Langbaum JB, Coello N, Riviere ME, Ryan JM, Lopez CL, Graf A; National Alzheimer’s Coordinating Center; Alzheimer’s Disease Neuroimaging Initiative. Caputo A, et al. Among authors: coello n. Alzheimers Res Ther. 2023 Mar 6;15(1):45. doi: 10.1186/s13195-023-01183-z. Alzheimers Res Ther. 2023. PMID: 36879340 Free PMC article.
Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study.
Muurling M, de Boer C, Kozak R, Religa D, Koychev I, Verheij H, Nies VJM, Duyndam A, Sood M, Fröhlich H, Hannesdottir K, Erdemli G, Lucivero F, Lancaster C, Hinds C, Stravopoulos TG, Nikolopoulos S, Kompatsiaris I, Manyakov NV, Owens AP, Narayan VA, Aarsland D, Visser PJ; RADAR-AD Consortium. Muurling M, et al. Alzheimers Res Ther. 2021 Apr 23;13(1):89. doi: 10.1186/s13195-021-00825-4. Alzheimers Res Ther. 2021. PMID: 33892789 Free PMC article.
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, Ludwig I, Willi R, Zalesak M, Ramanathan K, Kieseier BC, Häring DA, Bagger M, Fox E. Bar-Or A, et al. Among authors: coello n. Neurol Ther. 2023 Feb;12(1):303-317. doi: 10.1007/s40120-022-00427-8. Epub 2022 Dec 19. Neurol Ther. 2023. PMID: 36534274 Free PMC article.
Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research.
Erdemli G, Grammatikopoulou M, Wagner B, Vairavan S, Curcic J, Aarsland D, Wittenberg G, Nikolopoulos S, Muurling M, Froehlich H, de Boer C, Shanbhag NM, Nies VJM, Coello N, Gove D, Diaz A, Foy S, Dartee W, Brem AK. Erdemli G, et al. Among authors: coello n. NPJ Digit Med. 2024 Sep 4;7(1):232. doi: 10.1038/s41746-024-01211-8. NPJ Digit Med. 2024. PMID: 39232033 Free PMC article.
Estimands-What they are and why they are important for pharmacometricians.
Akacha M, Bartels C, Bornkamp B, Bretz F, Coello N, Dumortier T, Looby M, Sander O, Schmidli H, Steimer JL, Vong C. Akacha M, et al. Among authors: coello n. CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):279-282. doi: 10.1002/psp4.12617. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33951755 Free PMC article. No abstract available.
18 results